Index Ventures may be best known on these pages for its technology investments, but today it launched a new fund that points to how the company is willing to put its money into other examples of strong innovation. The life sciences fund will see Index put in $100 million of its own capital, and have it matched by $50 million each from big pharma leaders GlaxoSmithKline and Johnson & Johnson. Much like the new $400 million fund from Iris Capital, Orange and Publicis, this fund is all about bringing in major players into an environment where they can make more investments into the technologies and services that could well be the future of their industries, but have possibly been too difficult to track and engage with up to now. This time around, the focus is not tech per se, but promising, early-stage R&D innovation in health.Source: http://feedproxy.google.com/~r/Techcrunch/~3/8CeMrFbpAn4/
blagojevich new mexico state kevin rose sessions march madness scores doonesbury mike adams
কোন মন্তব্য নেই:
একটি মন্তব্য পোস্ট করুন